Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
61. |
ECCT/25/06/01 | Neosep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Christine Nafula Manyasi Site(s) in Kenya 1. Mbagathi County Referral Hospital (Nairobi City county) |
02-10-2025 |
View |
62. |
ECCT/25/06/02 | Neosep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Nayirat Mohamed Dormohamed Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) |
02-10-2025 |
View |
63. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
16-09-2025 |
View |
64. |
ECCT/25/02/11 | Extended Dosing OCV Trial A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya |
Principal Investigator(s) 1. Samuel Kariuki Site(s) in Kenya MMM MUKURU HEALTH CENTRE |
16-07-2025 |
View |
65. |
ECCT/25/03/04 | Ndovu RCT Investigating the optimal management of dolutegravir resistance: an open-label randomised controlled trial of maintaining dolutegravir or switch to ritonavir-boosted darunavir |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Bomu Hospital (Mombasa county) |
14-07-2025 |
View |
66. |
ECCT/24/11/03 | REALISE STUDY PROTOCOL A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children |
Principal Investigator(s) 1. Alejandro Javier Krolewiecki Site(s) in Kenya Kwale county |
19-06-2025 |
View |
67. |
ECCT/25/02/10 | PrEP My Way II PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP |
17-06-2025 |
View |
68. |
ECCT/25/02/09 | DASH II Study Diagnostic Access to Self-Care & Health Services in Low- and Middle-Income Countries (DASH) – Phase II Study |
Principal Investigator(s) 1. ELIZABETH ANNE BUKUSI Site(s) in Kenya Migori County |
23-05-2025 |
View |
69. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
21-05-2025 |
View |
70. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
20-05-2025 |
View |